Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)

NCT04216290 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04216290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04216290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 17, 2021
Completion date
May 19, 2027
Enrollment
11 (actual)
Sites
216

Conditions

As the registry lists them; a condition with its own page is linked.

bladder urothelial carcinoma, stage iii bladder cancer ajcc v8